Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
August 08, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q...
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 31, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
June 27, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 10, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection...
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 02, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care...
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
May 01, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at...
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
April 26, 2023 13:00 ET
|
Amicus Therapeutics, Inc.
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the...
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
March 27, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component...
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
March 01, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and...
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 27, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference...